Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Bridge Bio Starts Trial of Novel EGFR Inhibitor for NSCLC with Mutations

publication date: Apr 7, 2021

Bridge Biotherapeutics of Korea has started a Phase I/II trial of a novel EGFR inhibitor in non-small cell lung cancer (NSCLC) patients with a specific mutation. BBT-176 will be tested in NSCLC patients who progressed following prior therapy with an EGFR TKI agent. BBT-176 is designed to inhibit the signaling pathway of EGFR with C797S mutations, which causes resistance to osimertinib (Tagrisso). In China, Bridge Bio is a resident company of JLABS @ Shanghai, a Johnson & Johnson incubator. More details....

Stock Symbol: (KOSDAQ: 288330)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital